A Phase 4 interventional study of Insulin glargine 300 U/mL and Insulin degludec 100 U/mL in Type 2 Diabetes Mellitus and Renal Impairment, sponsored by Sanofi. Terminated at 68 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 139th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2022, is one of 103 in phase 4, and was the 166th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 151st largest by enrollment of the 178 interventional ones that give a count, is one of 5 that started in 2022, is one of 75 in phase 4, and was the 180th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The TRENT trial is designed to confirm the efficacy and safety of Gla-300 compared with IDeg-100 in insulin-naïve patient (participants who have not tried insulin) with Type 2 Diabetes Mellitus (T2DM) and renal impairment. It will test the hypothesis that Gla-300 is non-inferior to IDeg-100 with glucose control. If achieved, the trial will also test for the superiority of Gla-300 compared with IDeg-100 in Hemoglobin A1c (HbA1c) reduction, without an increased potential risk of hypoglycemia.
The trial will consist of the following periods:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gla-300 will be administered once daily for 24 weeks
Drug: Insulin glargine 300 U/mL
Ideg-100 will be administered once daily for 24 weeks
Drug: Insulin degludec 100 U/mL
Drug page: Insulin Glargine
Insulin glargine 300 U/mL in the SoloStar pen, self-administered once daily for 24 weeks.
Also known as: Toujeo, HOE901-U300
Drug page: Insulin degludec
Insulin degludec 100 U/mL will be self- administered once daily for 24 weeks.
Also known as: Tresiba
Difference in the Mean Change From Baseline to Week 24 in HbA1c Level (Gla-300 vs IDeg-100)
Change in HbA1c was calculated by subtracting baseline value from Week 24 value and then mean values were calculated.
Time frame: Baseline to 24 weeks
Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24
Change in FPG was calculated by subtracting baseline value from the Week 24 value.
Time frame: Baseline to 24 weeks
Change in Fasting Self-Measured Plasma Glucose (SMPG) From Baseline to Week 24
Change in SMPG was calculated by subtracting baseline value from the Week 24 value.
Time frame: Baseline to 24 weeks
Change in 7-point SMPG Profiles From Baseline to Week 24, Per Time Point Within 24-hour Period
7-point SMPG profiles were measured at the following 7 points: pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.
Time frame: Baseline to 24 weeks
Percentage of Participants Reaching HbA1c Target of <7.0% at Week 24
If a patient has a missing HbA1c value at Week 24, it is assumed that they did not reach the HbA1c target of \<7.0%. HbA1c value of 7.0% is equivalent to 53.0 mmol/mol.
Time frame: At week 24
Percentage of Participants With ≥1 Episode(s) of Confirmed Hypoglycemia Event (Cut-off Value 70 mg/dL and 54 mg/dL) During the 24-week Treatment Period.
Any event recorded with Yes as response to the question, "Was a glucose measurement obtained at the time of the event before countermeasure?" and a measurable glucose level of \<70 mg/dL. ADA (American Diabetes Association), Level 1 was defined as a measurable glucose concentration of \<70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L).
Time frame: Baseline to end of study (25 weeks)
Rate of Hypoglycemia Per Participant-year
Computed as: 365.25/12 × (number of episodes of hypoglycemia)/(number of days exposed in time window)
Time frame: Baseline to end of study (25 weeks)]
Percentage of Participants and Event Rate of Hypoglycemia by Trial Period (for ≤12 Weeks, for >13 Weeks to ≤24 Weeks)
Hypoglycemic events measured at the following intervals: Weeks 1-12 and Weeks 13-24.
Time frame: Baseline to end of study (25 weeks)
The 24-hour (All Time), Occurrence of Each Episode of Documented Hypoglycemia by Category, Presented by 2-hour Timeframe Over 24 Hours During the 24-week Treatment Period.
The time range for this outcome measure was 00:00 to 05:59, both inclusive. Hypoglycemia Categories \[(symptomatic, asymptomatic, severe) are defined per the American Diabetes Association/European Association for the Study of Diabetes hypoglycemia Classification\]
Time frame: Baseline to end of study (25 weeks)
Number of Participants With Adverse Events (AEs)) and Serious Adverse Events (SAEs), Including Adverse Events of Special Interest (AESIs)
Adverse events (AEs) and serious adverse events (SAEs), including adverse events of special interest (AESIs), and other safety evaluations, including vital signs and body weight.
Time frame: Baseline to end of study (25 weeks)
The study was conducted at 68 study centers across 5 countries. A total of 182 participants were screened between 05 December 2022 and 30 June 2023, of whom 120 were screen failures. The number of randomized participants remained significantly lower (\<10%) than was originally planned. Consequently, the estimated results would have been delayed by several years. Hence, the sponsor made the strategic decision to discontinue the trial due to this significant recruitment delay, not related safety.
| Milestone | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Started | 31 | 31 |
| Completed | 1 | 1 |
| Not completed | 30 | 30 |
| Withdrew: Study was terminated by the sponsor due to poor recruitment/severe recruitment delay | 30 | 30 |
Change in HbA1c was calculated by subtracting baseline value from Week 24 value and then mean values were calculated.
| percentage of HbA1c | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Difference in the Mean Change From Baseline to Week 24 in HbA1c Level (Gla-300 vs IDeg-100) | -0.4 ± 1.73 | -1.0 ± 0.98 |
Change in FPG was calculated by subtracting baseline value from the Week 24 value.
| (mg/dL) | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24 | -36.4 ± 25.16 | -55.5 ± 22.67 |
Change in SMPG was calculated by subtracting baseline value from the Week 24 value.
| (mmol/L) | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Change in Fasting Self-Measured Plasma Glucose (SMPG) From Baseline to Week 24 | -4.00 | — |
7-point SMPG profiles were measured at the following 7 points: pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.
| (mmol/L) | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| 7-Point SMPG Profile (mmol/L), before breakfast (fasting) | -4.13 | — |
| 7-Point SMPG Profile (mmol/L), 2 hours after breakfast | -1.30 | — |
| 7-Point SMPG Profile (mmol/L), before lunch | 0.31 | — |
| 7-Point SMPG Profile (mmol/L), 2 hours after lunch | 0.63 | — |
| 7-Point SMPG Profile (mmol/L), before dinner | 2.18 | — |
| 7-Point SMPG Profile (mmol/L), 2 hours after dinner | -5.36 | — |
| 7-Point SMPG Profile (mmol/L), at bedtime | -6.20 | — |
If a patient has a missing HbA1c value at Week 24, it is assumed that they did not reach the HbA1c target of \<7.0%. HbA1c value of 7.0% is equivalent to 53.0 mmol/mol.
| Participants | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Percentage of Participants Reaching HbA1c Target of <7.0% at Week 24 | 4 | 2 |
Any event recorded with Yes as response to the question, "Was a glucose measurement obtained at the time of the event before countermeasure?" and a measurable glucose level of \<70 mg/dL. ADA (American Diabetes Association), Level 1 was defined as a measurable glucose concentration of \<70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L).
| percentage of participants | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Percentage of Participants With ≥1 Episode(s) of Confirmed Hypoglycemia Event (Cut-off Value 70 mg/dL and 54 mg/dL) During the 24-week Treatment Period. | 35.5 | 29.0 |
Computed as: 365.25/12 × (number of episodes of hypoglycemia)/(number of days exposed in time window)
| Rate of hypoglycemia per patient-year | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Rate of Hypoglycemia Per Participant-year | 9.5 | 5.6 |
Hypoglycemic events measured at the following intervals: Weeks 1-12 and Weeks 13-24.
| Participants | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Titration period (Week 1 to Week 12) | 9 | 7 |
| Maintenance period (Week 13 to Week 24) | 5 | 5 |
The time range for this outcome measure was 00:00 to 05:59, both inclusive. Hypoglycemia Categories \[(symptomatic, asymptomatic, severe) are defined per the American Diabetes Association/European Association for the Study of Diabetes hypoglycemia Classification\]
| Episodes | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| The 24-hour (All Time), Occurrence of Each Episode of Documented Hypoglycemia by Category, Presented by 2-hour Timeframe Over 24 Hours During the 24-week Treatment Period. | 11 | 9 |
Adverse events (AEs) and serious adverse events (SAEs), including adverse events of special interest (AESIs), and other safety evaluations, including vital signs and body weight.
| Participants | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Adverse Event (AE) | 5 | 7 |
| Serious Adverse Event | 1 | 3 |
| Adverse Event of Special Interest (AESIs) | 0 | 0 |
| Treatment-Emergent SAEs | 1 | 3 |
Collected over All AEs (serious or nonserious) will be recorded from the signing of the ICF until the safety follow-up visit, patient's permanent discontinuation from the trial, or loss to follow-up, up to 25 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gla-300 U/mL Arm | 0/31 (0%) | 1/31 (3.2%) | 0/31 (0%) |
| IDeg-100 U/mL Arm | 1/31 (3.2%) | 3/31 (9.7%) | 5/31 (16.1%) |
| Event | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| Hypertensive Heart DiseaseCardiac disorders | 0/31 | 1/31 |
| Hypoglycemic EventMetabolism and nutrition disorders | 0/31 | 1/31 |
| Retinal artery occlusionEye disorders | 0/31 | 1/31 |
| Cardiac failure congestiveCardiac disorders | 0/31 | 1/31 |
| Circulatory collapseVascular disorders | 1/31 | 0/31 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/31 | 1/31 |
| Event | Gla-300 U/mL Arm | IDeg-100 U/mL Arm |
|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 0/31 | 3/31 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/31 | 2/31 |
| Age, Categorical(Participants) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 12 |
| >=65 years | 25 | 25 | 50 |
| Age, Continuous(years) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| Mean | 71.9 ± 7.5 | 71.0 ± 7.7 | 71.5 ± 7.5 |
| Sex: Female, Male(Participants) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| Female | 16 | 15 | 31 |
| Male | 15 | 16 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 6 | 8 |
| Not Hispanic or Latino | 29 | 25 | 54 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 27 | 29 | 56 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| Hungary | 3 | 6 | 9 |
| United States | 7 | 9 | 16 |
| Czechia | 5 | 3 | 8 |
| Poland | 12 | 9 | 21 |
| Serbia | 4 | 4 | 8 |
| Weight (kg)(kg) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| Mean | 89.5 ± 25.30 | 89.5 ± 20.32 | 89.5 ± 22.74 |
| BMI (kg//m²)((kg/m²)) | Gla-300 Arm | IDeg-100 Arm | Total |
|---|---|---|---|
| Mean | 31.6 ± 5.54 | 32.2 ± 6.56 | 31.9 ± 6.03 |
11 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2022 to primary completion in Jul 2023, 7 months.
Results were first posted in Sep 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine